Drug Profile
MM 161
Alternative Names: MM-161Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Merrimack Pharmaceuticals
- Class Antibodies; Antineoplastics
- Mechanism of Action Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer